This article is more than 5 years old. Information may no longer be current.
Top stories in dermatology: Hidradenitis suppurative trial, risk for serious infections in AD
Click Here to Manage Email Alerts
IFX-1, a monoclonal anti-human complement factor C5a antibody, showed no significant dose response in patients with hidradenitis at week 16 of the SHINE phase 2b study, in the top Healio Dermatology story from last week.
In other top news, for adults with atopic dermatitis, treatment with cyclosporine or methotrexate appears to have a lower rate of serious infections than mycophenolate, azathioprine and systemic prednisone.
No significant treatment effect found for IFX-1 in hidradenitis suppurativa trial
The treatment blocks the biological activity of C5a and leaves the formation of the membrane attack complex intact as a defense mechanism. Read more.
Cyclosporine, methotrexate pose less risk for serious infections in atopic dermatitis
“These findings may help inform clinicians in their selection of medications for patients requiring systemic therapy for atopic dermatitis,” Maria C. Schneeweiss, MD, of the departments of dermatology and medicine in the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital, and colleagues wrote. Read more.
Depression, anxiety in alopecia elevated in adults, those with more hair loss
The researchers found a positive relationship with anxiety (OR = 2.5; 95% CI, 1.54-4.06) and depression (OR = 2.71; 95% CI, 1.52-4.82). Read more.